2023-09-30 09:15:00 ET
Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key to making the company a success. The company uses machine learning and believes it can help modernize drug discovery.
Earlier this year, hype around the business reached a fever pitch after it announced an investment from tech company Nvidia . But is there more to Recursion than just hype? Is this stock the real deal, and is it worth investing in right now?
Recursion doesn't generate much revenue today -- not nearly enough to cover its expenses. It has multiple programs in its pipeline, which focuses on rare diseases and cancer, but nothing is beyond phase 2 trials right now. This means that investors may have to wait years for the company to generate significant revenue -- assuming it is successful in its efforts.
For further details see:
Is Recursion Pharmaceuticals Stock a Buy?